A 32-year-old man with bipolar disorder and alcohol use disorder presented to the emergency department (ED) with dyspnea, chest pain, and abdominal pain. He was tachycardic, normotensive, and well oxygenated on presentation. Complete blood count, comprehensive metabolic panel, and cardiac enzymes were all within normal limits. Valproic acid level was low (12.1 mcg/mL). Drug screen was negative. Electrocardiogram showed normal sinus rhythm, inferolateral ischemia, and possibly an old anteroseptal infarct. He was treated with 5 mg of intravenous (IV) metoprolol, 1 mg of IV lorazepam, and aspirin, and then discharged from the ED.
Twenty-four hours later, he was found sitting on the ambulance ramp outside the ED, apparently unmoved since his discharge. He again complained of chest pain and diffuse abdominal pain. Vital signs and laboratory tests were unchanged from his previous evaluation. Chest X-ray was normal. Due to his flat affect, slow speech, and confused mental state, a computed tomography (CT) scan of his head was obtained and was normal. Psychiatry was consulted due to concern for catatonia.
On initial psychiatric examination, he was found to be tremulous, diaphoretic, and resistant to arm flexion and extension. He made repetitive, purposeless movements and stared into space. He was slow to respond verbally and had periods of mutism. After receiving IV fluids and a 1-mg dose of IV lorazepam, his tremors and purposeless movements decreased and his speech became more fluent. He was also able to make better eye contact and to eat, drink, and ambulate. He agreed to admission to the inpatient psychiatric unit.
Once admitted, the patient's confusion and rigidity returned. Additional medical testing included a nonreactive rapid plasma reagin, negative HIV, negative blood and urine cultures, and normal urinalysis, thyroid-stimulating hormone, erythrocyte sedimentation rate, C-reactive protein, cortisol, ceruloplasmin, copper, and urine porphobilinogen. The internal medicine and neurology teams found no organic explanation for his presentation. Magnetic resonance imaging (MRI) of the brain with and without contrast was normal. A repeat CT scan of the head showed no acute changes but "mild diffuse cerebral volume loss, greater than expected for patient's age," not significantly changed from the initial CT head scan.
The patient was prescribed lorazepam at a dose of 2 mg intramuscularly (IM) 3 times daily and had improvement in alertness, eye contact, and thought process. Quetiapine was added for mood stabilization. Throughout his hospitalization, with each attempt to wean him off lorazepam and increase his mood stabilizer, his catatonia returned. And with each increase in his lorazepam dose, sedation and unsteadiness became more problematic. He was started on caffeine at 200 mg daily to combat sedation and paroxetine at 20 mg daily for depressed mood/motivation. His flat affect and negativism persisted, although his rigidity improved. As the dose of lorazepam was decreased, he was switched from quetiapine to risperdal, with the plan to transition him to the long-acting injectable formulation for better outpatient compliance. However, he experienced an episode of acute chest pain and tachycardia, although he had no new electrocardiogram changes or abnormal cardiac enzymes or D-dimer. After receiving IV lorazepam, his symptoms resolved and he was able to communicate, eat, drink, and ambulate. He was switched back to quetiapine and oral (PO) lorazepam was again increased. Quetiapine and paroxetine were eventually discontinued due to minimal improvement, and lurasidone was initiated for mood stabilization. However, he again experienced an episode of tachycardia, diaphoresis, rigidity, and altered awareness, which improved with 1 mg of lorazepam. Lurasidone was stopped. Lorazepam was increased up to 16 mg/day, but at this dose he experienced dizziness and a fall without injury. After 2 months, there was a lack of improvement in his catatonia. His Bush-Francis catatonia score remained high at 17. 1 Other treatment options were investigated.
Attempts were made to transfer him to an inpatient facility for ECT, but his insurance would not cover the cost of that treatment. Outpatient electroconvulsive therapy (ECT) was not considered a safe option because of his history of poor compliance, poor social support, and alcohol abuse.
Additional treatment options were explored to supplement treatment with lorazepam. The patient was given divalproex, which was titrated to 500 mg twice daily (BID) (drug level 99.7), and memantine, titrated up to 5 mg every morning (qAM) and 10 mg at bedtime (qHS). He appeared to have marked improvement of his flat affect and less cogwheel rigidity. He could stand more quickly, ambulate more fluidly, and engage in conversation. His Mini-Mental State Examination score improved from 13 to 16. At this point, he was discharged on divalproex at 500 mg BID, lorazepam at 2 mg PO 4 times daily, and memantine at 5 mg PO qAM and 10 mg PO qHS. He was sent to the Addiction Prevention and Recovery Administration (APRA) for an inpatient program to detox from lorazepam and to address alcohol abuse.
To our surprise, he was not accepted to the APRA program and was readmitted to the hospital. He was cross-tapered from lorazepam to chlordiazepoxide 25 mg PO 3 times daily (TID), which was then slowly tapered off. Memantine was increased to 10 mg BID.
He initially responded to this treatment, became more conversant, and attended therapy groups.
However, he continued to have residual symptoms of catatonia including waxy flexibility, catalepsy, and poor nutritional intake. He was prescribed oral mirtazapine at a dose of 15 mg daily to stimulate his appetite, with some improvement. Unfortunately, while awaiting placement, he entered an excited catatonic state and attacked a staff member, remaining mute immediately after the incident. After this incident, oral lorazepam at 2 mg TID was restarted and the patient had an improvement in his catatonic symptoms, including catalepsy, mutism, and delayed speech. Divaloprex, mirtazapine, and memantine were also continued. For the following 2 weeks, he did not exhibit further signs of excited catatonia.
Benzodiazepine-Resistant Catatonia

D I A G N O S I S
DISCUSSION
Catatonia is a psychomotor disorder that presents in various ways, but most commonly in an excited, retarded state, or malignant way. Excited catatonia is characterized by excessive and purposeless movements in the extremities, restlessness, stereotypy, impulsivity, frenzy, and combativeness. 2, 3 Retarded catatonia is characterized by mutism, inhibited movement, posturing, negativism, staring, and, in more severe cases, decreased oral intake, stupor, and incontinence. Malignant catatonia is characterized by autonomic instability, delirium, and rigidity. 2, 3 Catatonia is a psychomotor disorder that presents in various ways.
case challenge Catatonia occurs in the context of an underlying psychiatric or general medical disorder, such as schizophrenia, bipolar disorder, major depressive disorder, or infectious, metabolic, neurologic, and rheumatologic disorders. First-line treatments are benzodiazepines, specifically lorazepam, and ECT. Lorazepam at a dose of 0.5 to 2 mg given IV or IM is diagnostic if there is marked improvement of catatonic symptoms after one treatment. Continuing treatment with lorazepam, up to 16 mg/day until symptoms improve, helps the majority of patients. 2 However, some patients do not respond to benzodiazepines, become resistant to them, or cannot tolerate their side effects, which include confusion, delirium, dizziness, and sedation. 2 With other patients, the use of benzodiazepines may be problematic due to untreated alcohol dependence. Recent reports show memantine and divalproex to be alternatives to benzodiazepineresistant catatonia. [2] [3] [4] [5] [6] [7] [8] This case report demonstrates the combination of memantine and divalproex as an alternative to lorazepam and ECT in the treatment of catatonia.
This case report adds to the sparse literature available on alternative treatment options for benzodiazepine-resistant catatonia, including memantine and divalproex.
2,4-9 Although other case reports have been published about the use of these individual medications, we believe this is the first report that discusses the combination of memantine and divalproex to treat catatonia.
It is thought that catatonia results from an imbalance of gammaaminobutyric acid (GABA), dopamine (D2), and glutamate. Decreased activity at the D2 receptor seems to cause an abundant release of glutamate, the major excitatory neurotransmitter in the brain. Additionally, decreased activity of GABA, the major inhibitory neurotransmitter in the brain, leads to a further increase in glutamate activity through the loss of inhibitory signals. It is postulated that catatonia develops when these neurochemical changes alter the neural circuit involving the medial gyrus of the orbital frontal lobe, the lateral gyrus, caudate nucleus, globus pallidus, and thalamus. Excessive glutamate at the posterior parietal lobe seems to contribute to posturing in catatonia. Aberrant signaling in the supplemental motor area (SMA) appears to play a role in the bradykinesia, rigidity, and other Parkinsonism symptoms of catatonia. The SMA feeds back to the medial orbital gyrus, where GABA is deficient, completing the neural circuit. 2 Memantine is a noncompetitive N-methyl-D-aspartate (NMDA) antagonist that is currently approved by the US Food and Drug Administration for Alzheimer's disease. Prior cases reports have suggested that catatonic patients respond to memantine through its direct (NMDA) antagonism and consequent reduction in glutamate excitotoxicity. 8 Another less frequently reported treatment option is divalproex, an anticonvulsant. Divalproex is currently approved for the treatment of epilepsy, bipolar disorder, and migraine headaches. Divalproex increases GABA levels, inhibits sodium and calcium channels, and inhibits glutamate/NMDA. 9 It has been reported in a few case reports to improve catatonia resistant to lorazepam; however, it may take longer than lorazepam to see a response.
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CONCLUSION
This case report presents a novel approach to treating lorazepamresistant catatonia with a combination of memantine and divalproex. Although recent studies have discussed the benefits of using memantine, additional research is needed regarding the implications and potential use of this unique combination.
